The major facilitative folate transporters solute carrier 19A1 and solute carrier 46A1: Biology and role in antifolate chemotherapy of cancer

Drug Metabolism and Disposition

Volumn 42, Issue 4, 2014, Pages 632-649

  Matherly, Larry H ^a,b   Wilson, Mike R ^a   Hou, Zhanjun ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10 PROPARGYL 5,8 DIDEAZAFOLIC ACID; 2 [5 [[(1,2 DIHYDRO 3 METHYL 1 OXOBENZO[F]QUINAZOLIN 9 YL)METHYL]AMINO] 1 OXO 2 ISOINDOLINYL]GLUTARIC ACID; AMINOPTERIN; BGC 9331; DIHYDROFOLATE REDUCTASE INHIBITOR; FOLIC ACID ANTAGONIST; GW 1843U 89; LOMETREXOL; METHOTREXATE; PEMETREXED; PLEVITREXED; PRALATREXATE; PROTON COUPLED FOLATE TRANSPORTER; PURINE ANTAGONIST; PURINE NUCLEOTIDE BIOSYNTHESIS INHIBITOR DERIVATIVE; RALTITREXED; REDUCED FOLATE CARRIER; TALOTREXIN; THYMIDYLATE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; BILE DUCT CANCER; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CROHN DISEASE; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TRANSPORT; ENZYME SUBSTRATE COMPLEX; FOLATE METABOLISM; FOLIC ACID DEFICIENCY; GENE DELETION; GENE EXPRESSION REGULATION; HUMAN; LEUKEMIA; LIVER CANCER; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LYMPHOMA; MEMBRANE TRANSPORT; METASTATIC COLORECTAL CANCER; MOLECULAR PATHOLOGY; MUCOSA INFLAMMATION; NEPHROTOXICITY; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PANCREAS CANCER; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; PROTEIN PROCESSING; PROTEIN TRANSPORT; PSORIASIS; RHEUMATOID ARTHRITIS; SHORT SURVEY; SOLID TUMOR; STOMACH CANCER; STRUCTURE ACTIVITY RELATION; T CELL LYMPHOMA; TRANSCRIPTION REGULATION;

AMINOPTERIN; ANIMALS; DRUG RESISTANCE, NEOPLASM; FOLIC ACID; FOLIC ACID ANTAGONISTS; HUMANS; METHOTREXATE; NEOPLASMS; PROTON-COUPLED FOLATE TRANSPORTER; REDUCED FOLATE CARRIER PROTEIN;

EID: 84896133047     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.055723     Document Type: Short Survey

References (240)

1. Abramson J, Smirnova I, Kasho V, Verner G, Kaback HR, and Iwata S (2003) Structure and mechanism of the lactose permease of Escherichia coli. Science 301:610-615. (Pubitemid 36927939)
2. Allegra CJ, Fine RL, Drake JC, and Chabner BA (1986) The effect of methotrexate on intracellular folate pools in human MCF-7 breast cancer cells. Evidence for direct inhibition of purine synthesis. J Biol Chem 261:6478-6485. (Pubitemid 17204161)
3. Alvarez-Fernandez C, Perez-Arnillas Q, Ruiz-Echeverria L, Rodriguez-Rubi D, Sanchez-Lorenzo L, Li-Torres W, Izquierdo-Manuel M, Berros JP, Luque-Cabal M, and Jimenez-Fonseca P, et al. (2013) Reduced folate carrier (RFC) as a predictive marker for response to pemetrexed in advanced non-small cell lung cancer (NSCLC). Invest New Drugs [published ahead of print].
4. Atabay B, Turker M, Ozer EA, Mahadeo K, Diop-Bove N, and Goldman ID (2010) Mutation of the proton-coupled folate transporter gene (PCFT-SLC46A1) in Turkish siblings with hereditary folate malabsorption. Pediatr Hematol Oncol 27:614-619.
5. Beardsley GP, Moroson BA, Taylor EC, and Moran RG (1989) A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis. J Biol Chem 264:328-333. (Pubitemid 19027608)
6. Beutel G, Glen H, Schoffski P, Chick J, Gill S, Cassidy J, and Twelves C (2005) Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors. Clin Cancer Res 11(15):5487-5495. (Pubitemid 41060825)
7. Bissett D, McLeod HL, Sheedy B, Collier M, Pithavala Y, Paradiso L, Pitsiladis M, and Cassidy J (2001) Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034. Br J Cancer 84:308-312. (Pubitemid 32154421)
8. Boritzki TJ, Barlett CA, Zhang C, and Howland EF (1996) AG2034: a novel inhibitor of glycinamide ribonucleotide formyltransferase. Invest New Drugs 14:295-303. (Pubitemid 26383944)
9. Brandsch C, Zibolka J, Frommhagen M, Lehmann U, Dierkes J, Kühne H, Hirche F, and Stangl GI (2013) Vitamin D is not linked to folate status and mRNA expression of intestinal proton-coupled folate transporter. Eur J Nutr [published ahead of print].
10. Brigle KE, Spinella MJ, Sierra EE, and Goldman ID (1995) Characterization of a mutation in the reduced folate carrier in a transport defective L1210 murine leukemia cell line. J Biol Chem 270:22974-22979.
11. Bronder JL and Moran RG (2003) A defect in the p53 response pathway induced by de novo purine synthesis inhibition. J Biol Chem 278:48861-48871.
12. Budman DR, Johnson R, Barile B, Bowsher RR, Vinciguerra V, Allen SL, Kolitz J, Ernest CS, 2nd, Kreis W, and Zervos P, et al. (2001) Phase I and pharmacokinetic study of LY309887: a specific inhibitor of purine biosynthesis. Cancer Chemother Pharmacol 47:525-531. (Pubitemid 32477300)
13. Burckhardt G (2012) Drug transport by Organic Anion Transporters (OATs). Pharmacol Ther 136:106-130.
14. Cao W and Matherly LH (2003) Characterization of a cysteine-less human reduced folate carrier: localization of a substrate-binding domain by cysteine-scanning mutagenesis and cysteine accessibility methods. Biochem J 374:27-36. (Pubitemid 37046925)
15. Cario H, Bode H, Debatin KM, Opladen T, and Schwarz K (2009) Congenital null mutations of the FOLR1 gene: a progressive neurologic disease and its treatment. Neurology 73:2127-2129.
16. Chancy CD, Kekuda R, Huang W, Prasad PD, Kuhnel JM, Sirotnak FM, Roon P, Ganapathy V, and Smith SB (2000) Expression and differential polarization of the reduced-folate transporter-1 and the folate receptor alpha in mammalian retinal pigment epithelium. J Biol Chem 275:20676-20684. (Pubitemid 30457655)
17. Chang AB, Lin R, Keith Studley W, Tran CV, and Saier MH, Jr (2004) Phylogeny as a guide to structure and function of membrane transport proteins. Mol Membr Biol 21:171-181. (Pubitemid 38745646)
18. Chattopadhyay S, Moran RG, and Goldman ID (2007) Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 6:404-417. (Pubitemid 46332443)
19. Chello PL, Sirotnak FM, Wong E, Kisliuk RL, Gaumont Y, and Combepine G (1982) Further studies stereospecificity at carbon 6 for membrane transport of tetrahydrofolates. Diastereoisomers of 5-methyltetrahydrofolates as competitive inhibitors of transport of methotrexate in L1210 cells. Biochem Pharmacol 31:1527-1530. (Pubitemid 12161769)
20. Cherian C, Kugel Desmoulin S, Wang L, Polin L, White K, Kushner J, Stout M, Hou Z, Gangjee A, and Matherly LH (2013) Therapeutic targeting malignant mesothelioma with a novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate via its selective uptake by the proton-coupled folate transporter. Cancer Chemother Pharmacol 71:999-1011.
21. Chládek J, Martínková J, Simková M, Vanecková J, Koudelková V, and Nozicková M (1998) Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment. Eur J Clin Pharmacol 53:437-444.
22. Chu E, Callender MA, Farrell MP, and Schmitz JC (2003) Thymidylate synthase inhibitors as anticancer agents: from bench to bedside. Cancer Chemother Pharmacol 52 (Suppl 1):S80-S89. (Pubitemid 37047028)
23. Ciuleanu T, Diculescu M, Hoepffner NM, Trojan J, Sailer V, Zalupski M, Herrmann T, Roth A, Chick J, and Brock K, et al. (2007) A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers. Invest New Drugs 25:385-390. (Pubitemid 46944848)
24. Clamp AR, Schöffski P, Valle JW, Wilson RH, Marreaud S, Govaerts AS, Debois M, Lacombe D, Twelves C, and Chick J, et al.; EORTC New Drug Development Group (2008) A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 61:579-585.
25. Cohen MH, Cortazar P, Justice R, and Pazdur R (2010) Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC). Oncologist 15:1352-1358.
26. Cohen MH, Justice R, and Pazdur R (2009) Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer. Oncologist 14:930-935.
27. Cole PD, Drachtman RA, Masterson M, Smith AK, Glod J, Zebala JA, Lisi S, Drapala DA, and Kamen BA (2008) Phase 2B trial of aminopterin in multiagent therapy for children with newly diagnosed acute lymphoblastic leukemia. Cancer Chemother Pharmacol 62:65-75. (Pubitemid 351537847)
28. Deng Y, Hou Z, Wang L, Cherian C, Wu J, Gangjee A, and Matherly LH (2008) Role of lysine 411 in substrate carboxyl group binding to the human reduced folate carrier, as determined by site-directed mutagenesis and affinity inhibition. Mol Pharmacol 73:1274-1281. (Pubitemid 351439209)
29. Deng Y, Zhou X, Kugel Desmoulin S, Wu J, Cherian C, Hou Z, Matherly LH, and Gangjee A (2009) Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d] pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry. J Med Chem 52:2940-2951.
30. Desmoulin SK, Hou Z, Gangjee A, and Matherly LH (2012a) The human proton-coupled folate transporter: Biology and therapeutic applications to cancer. Cancer Biol Ther 13:1355-1373.
31. Desmoulin SK, Wang L, Polin L, White K, Kushner J, Stout M, Hou Z, Cherian C, Gangjee A, and Matherly LH (2012b) Functional loss of the reduced folate carrier enhances the antitumor activities of novel antifolates with selective uptake by the proton-coupled folate transporter. Mol Pharmacol 82:591-600.
32. Desmoulin SK, Wang Y, Wu J, Stout M, Hou Z, Fulterer A, Chang MH, Romero MF, Cherian C, and Gangjee A, et al. (2010) Targeting the proton-coupled folate transporter for selective delivery of 6-substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitors of de novo purine biosynthesis in the chemotherapy of solid tumors. Mol Pharmacol 78:577-587.
33. Diop-Bove N, Jain M, Scaglia F, and Goldman ID (2013) A novel deletion mutation in the proton-coupled folate transporter (PCFT; SLC46A1) in a Nicaraguan child with hereditary folate malabsorption. Gene 527:673-674.
34. Diop-Bove N, Kronn D, and Goldman ID (2008) Hereditary Folate Malabsorption, in GeneReviews (Pagon RA, Bird TD, Dolan CR, Stephens K, and Adam MP eds) University of Washington, Seattle, WA.
35. Diop-Bove NK, Wu J, Zhao R, Locker J, and Goldman ID (2009) Hypermethylation of the human proton-coupled folate transporter (SLC46A1) minimal transcriptional regulatory region in an antifolate-resistant HeLa cell line. Mol Cancer Ther 8:2424-2431.
36. Dixon KH, Lanpher BC, Chiu J, Kelley K, and Cowan KH (1994) A novel cDNA restores reduced folate carrier activity and methotrexate sensitivity to transport deficient cells. J Biol Chem 269:17-20. (Pubitemid 24026611)
37. Drori S, Jansen G, Mauritz R, Peters GJ, and Assaraf YG (2000a) Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake. J Biol Chem 275:30855-30863.
38. Drori S, Sprecher H, Shemer G, Jansen G, Goldman ID, and Assaraf YG (2000b) Characterization of a human alternatively spliced truncated reduced folate carrier increasing folate accumulation in parental leukemia cells. Eur J Biochem 267(3):690-702. (Pubitemid 30082381)
39. Duan P, Wu J, and You G (2011) Mutational analysis of the role of GXXXG motif in the function of human organic anion transporter 1 (hOAT1). Int J Biochem Mol Biol 2:1-7.
40. Duch DS, Banks S, Dev IK, Dickerson SH, Ferone R, Heath LS, Humphreys J, Knick V, Pendergast W, and Singer S, et al. (1993) Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase. Cancer Res 53:810-818. (Pubitemid 23077867)
41. Duddempudi PK, Nakashe P, Blanton MP, and Jansen M (2013) The monomeric state of the proton-coupled folate transporter represents the functional unit in the plasma membrane. FEBS J 280:2900-2915.
42. Elnakat H and Ratnam M (2004) Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev 56:1067-1084. (Pubitemid 38496508)
43. Eloranta JJ, Zaïr ZM, Hiller C, Häusler S, Stieger B, and Kullak-Ublick GA (2009) Vitamin D3 and its nuclear receptor increase the expression and activity of the human proton-coupled folate transporter. Mol Pharmacol 76:1062-1071.
44. Falk S, Anthoney A, Eatock M, Van Cutsem E, Chick J, Glen H, Valle JW, Drolet DW, Albert D, and Ferry D, et al. (2006) Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma. Br J Cancer 95:450-456. (Pubitemid 44232553)
45. Farber S (1949) Some observations on the effect of folic acid antagonists on acute leukemia and other forms of incurable cancer. Blood 4:160-167.
46. Farber S, Cutler EC, Hawkins JW, Harrison JH, Peirce EC, 2nd, and Lenz GG (1947) The Action of Pteroylglutamic Conjugates on Man. Science 106:619-621.
47. Farber S and Diamond LK (1948) Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med 238:787-793.
48. Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Gillies R, and Hopkins M, et al.; The North American Crohn's Study Group Investigators (1995) Methotrexate for the treatment of Crohn's disease. N Engl J Med 332:292-297.
49. Ferreri AJ, Dell'Oro S, Capello D, Ponzoni M, Iuzzolino P, Rossi D, Pasini F, Ambrosetti A, Orvieto E, and Ferrarese F, et al. (2004) Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas. Br J Haematol 126:657-664. (Pubitemid 39221300)
50. Flatley RM, Payton SG, Taub JW, and Matherly LH (2004) Primary acute lymphoblastic leukemia cells use a novel promoter and 59noncoding exon for the human reduced folate carrier that encodes a modified carrier translated from an upstream translational start. Clin Cancer Res 10(15):5111-5122. (Pubitemid 39099785)
51. Furumiya M, Inoue K, Ohta K, Hayashi Y, and Yuasa H (2013) Transcriptional regulation of PCFT by KLF4, HNF4a, CDX2 and C/EBPa: implication in its site-specific expression in the small intestine. Biochem Biophys Res Commun 431:158-163.
52. Gallagher FA, Kettunen MI, Day SE, Hu DE, Ardenkjaer-Larsen JH, Zandt Ri, Jensen PR, Karlsson M, Golman K, and Lerche MH, et al. (2008) Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate. Nature 453:940-943. (Pubitemid 351832568)
53. Geller J, Kronn D, Jayabose S, and Sandoval C (2002) Hereditary folate malabsorption: family report and review of the literature. Medicine (Baltimore) 81:51-68. (Pubitemid 34081287)
54. Gillies RJ, Raghunand N, Karczmar GS, and Bhujwalla ZM (2002) MRI of the tumor microenvironment. J Magn Reson Imaging 16:430-450. (Pubitemid 35167878)
55. Goldin A, Venditti JM, Humphreys SR, Dennis D, Mantel N, and Greenhouse SW (1955) A quantitative comparison of the antileukemic effectiveness of two folic acid antagonists in mice. J Natl Cancer Inst 15:1657-1664.
56. Goldman ID (1969) Transport energetics of the folic acid analogue, methotrexate, in L1210 leukemia cells. Enhanced accumulation by metabolic inhibitors. J Biol Chem 244:3779-3785.
57. Goldman ID (1971) The characteristics of the membrane transport of amethopterin and the naturally occurring folates. Ann N Y Acad Sci 186:400-422.
58. Goldman ID, Lichtenstein NS, and Oliverio VT (1968) Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell. J Biol Chem 243:5007-5017.
59. Goldman ID and Matherly LH (1985) The cellular pharmacology of methotrexate. Pharmacol Ther 28:77-102. (Pubitemid 15015465)
60. Gonen N and Assaraf YG (2010) The obligatory intestinal folate transporter PCFT (SLC46A1) is regulated by nuclear respiratory factor 1. J Biol Chem 285:33602-33613.
61. Gonen N and Assaraf YG (2012) Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat 15(4):183-210.
62. Gonen N, Bram EE, and Assaraf YG (2008) PCFT/SLC46A1 promoter methylation and restoration of gene expression in human leukemia cells. Biochem Biophys Res Commun 376:787-792.
63. Gregory JI (1995) The bioavailability of folate, Marcel Dekker, Inc., New York.
64. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, and Shaw RJ (2008) AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30:214-226. (Pubitemid 351626684)
65. Hainsworth J, Vergote I, and Janssens J (2003) A review of phase II studies of ZD9331 treatment for relapsed or refractory solid tumours. Anticancer Drugs 14 (Suppl 1):S13-S19. (Pubitemid 36951804)
66. Hanlon MH and Ferone R (1996) In vitro uptake, anabolism, and cellular retention of 1843U89 and other benzoquinazoline inhibitors of thymidylate synthase. Cancer Res 56:3301-3306. (Pubitemid 26242980)
67. Hazarika M, White RM, Jr, Booth BP, Wang YC, Ham DY, Liang CY, Rahman A, Gobburu JV, Li N, and Sridhara R, et al. (2005) Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res 11(3):982-992. (Pubitemid 40175745)
68. Henderson GB and Zevely EM (1983) Structural requirements for anion substrates of the methotrexate transport system in L1210 cells. Arch Biochem Biophys 221:438-446. (Pubitemid 13135505)
69. Hou Z, Cherian C, Drews J, Wu J, and Matherly LH (2010) Identification of the minimal functional unit of the homo-oligomeric human reduced folate carrier. J Biol Chem 285:4732-4740.
70. Hou Z, Kugel Desmoulin S, Etnyre E, Olive M, Hsiung B, Cherian C, Wloszczynski PA, Moin K, and Matherly LH (2012) Identification and functional impact of homo-oligomers of the human proton-coupled folate transporter. J Biol Chem 287:4982-4995.
71. Hou Z and Matherly LH (2009) Oligomeric structure of the human reduced folate carrier: identification of homo-oligomers and dominant-negative effects on carrier expression and function. J Biol Chem 284:3285-3293.
72. Hou Z, Orr S, Etnyre E, Cherian C, and Matherly LH (2013) Acute Regulation of Human Reduced Folate Carrier by Folates as a Novel Adaptive Mechanism to Folate Deprivation. Proceedings AACR 54:212.
73. Hou Z, Stapels SE, Haska CL, and Matherly LH (2005) Localization of a substrate binding domain of the human reduced folate carrier to transmembrane domain 11 by radioaffinity labeling and cysteine-substituted accessibility methods. J Biol Chem 280:36206-36213. (Pubitemid 41633893)
74. Hou Z, Ye J, Haska CL, and Matherly LH (2006) Transmembrane domains 4, 5, 7, 8, and 10 of the human reduced folate carrier are important structural or functional components of the transmembrane channel for folate substrates. J Biol Chem 281:33588-33596. (Pubitemid 46036739)
75. Howell SB, Mansfield SJ, and Taetle R (1981) Thymidine and hypoxanthine requirements of normal and malignant human cells for protection against methotrexate cytotoxicity. Cancer Res 41:945-950. (Pubitemid 11136341)
76. Huang Y, Lemieux MJ, Song J, Auer M, and Wang DN (2003) Structure and mechanism of the glycerol-3-phosphate transporter from Escherichia coli. Science 301:616-620. (Pubitemid 36927940)
77. Hughes LR, Stephens TC, Boyle FT, and Jackman AL (1999) Raltitrexed (Tomudex), a Highly Polyglutamatable Antifolate Thymidylate Synthase Inhibitor, in Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy (Jackman AL ed) pp 147-165, Humana Press, Inc., Totowa, NJ.
78. Ifergan I, Jansen G, and Assaraf YG (2008) The reduced folate carrier (RFC) is cytotoxic to cells under conditions of severe folate deprivation. RFC as a double edged sword in folate homeostasis. J Biol Chem 283:20687-20695.
79. Inoki K, Zhu T, and Guan KL (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell 115:577-590. (Pubitemid 37506046)
80. Inoue K, Nakai Y, Ueda S, Kamigaso S, Ohta KY, Hatakeyama M, Hayashi Y, Otagiri M, and Yuasa H (2008) Functional characterization of PCFT/HCP1 as the molecular entity of the carrier-mediated intestinal folate transport system in the rat model. Am J Physiol Gastrointest Liver Physiol 294:G660-G668. (Pubitemid 351468755)
81. Jackman AL and Calvert AH (1995) Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann Oncol 6(9):871-881.
82. Jackman AL, Kimbell R, Aherne GW, Brunton L, Jansen G, Stephens TC, Smith MN, Wardleworth JM, and Boyle FT (1997) Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase. Clin Cancer Res 3(6):911-921. (Pubitemid 27252939)
83. Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, Judson IR, and Hughes LR (1991) ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 51:5579-5586.
84. Jackson RC and Harkrader RJ (1981) The contributions of de-novo and salvage pathways of nucleotide biosynthesis in normal and malignant cells, in Nucleosides and Cancer Treatment (Tattersall MHN and Fox RM ed) pp 18-31, Academic Press, Sydney.
85. Jansen G (1999) Receptor- and carrier- mediated transport system for folates and antifolates, in Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy (Jackman AL ed) p 293, Humana Press Inc., Totowa, NJ.
86. Jansen G, Mauritz R, Drori S, Sprecher H, Kathmann I, Bunni M, Priest DG, Noordhuis P, Schornagel JH, and Pinedo HM, et al. (1998) A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J Biol Chem 273:30189-30198. (Pubitemid 28545482)
87. Jansen G, Westerhof GR, Jarmuszewski MJ, Kathmann I, Rijksen G, and Schornagel JH (1990) Methotrexate transport in variant human CCRF-CEM leukemia cells with elevated levels of the reduced folate carrier. Selective effect on carrier-mediated transport of physiological concentrations of reduced folates. J Biol Chem 265:18272-18277.
88. König J, Müller F, and Fromm MF (2013) Transporters and drug-drug interactions: important determinants of drug disposition and effects. Pharmacol Rev 65:944-966.
89. Krug LM, Azzoli CG, Kris MG, Miller VA, Khokhar NZ, Tong W, Ginsberg MS, Venkatraman E, Tyson L, Pizzo B, Baez V, Ng KK, and Sirotnak FM (2003) 10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer. Clin Cancer Res 9(6):2072-2078. (Pubitemid 36687627)
90. Kruh GD, Belinsky MG, Gallo JM, and Lee K (2007) Physiological and pharmacological functions of Mrp2, Mrp3 and Mrp4 as determined from recent studies on gene-disrupted mice. Cancer Metastasis Rev 26:5-14. (Pubitemid 46452179)
91. Kugel Desmoulin S, Wang L, Hales E, Polin L, White K, Kushner J, Stout M, Hou Z, Cherian C, and Gangjee A, et al. (2011) Therapeutic targeting of a novel 6-substituted pyrrolo [2,3-d] pyrimidine thienoyl antifolate to human solid tumors based on selective uptake by the proton-coupled folate transporter. Mol Pharmacol 80:1096-1107.
92. Kumar CK, Moyer MP, Dudeja PK, and Said HM (1997) A protein-tyrosine kinase-regulated, pH-dependent, carrier-mediated uptake system for folate in human normal colonic epithelial cell line NCM460. J Biol Chem 272:6226-6231. (Pubitemid 27118093)
93. Lasry I, Berman B, Straussberg R, Sofer Y, Bessler H, Sharkia M, Glaser F, Jansen G, Drori S, and Assaraf YG (2008) A novel loss-of-function mutation in the proton-coupled folate transporter from a patient with hereditary folate malabsorption reveals that Arg 113 is crucial for function. Blood 112:2055-2061.
94. Liu M, Ge Y, Cabelof DC, Aboukameel A, Heydari AR, Mohammad R, and Matherly LH (2005) Structure and regulation of the murine reduced folate carrier gene: identification of four noncoding exons and promoters and regulation by dietary folates. J Biol Chem 280:5588-5597. (Pubitemid 40280037)
95. Liu M, Ge Y, Payton SG, Aboukameel A, Buck S, Flatley RM, Haska C, Mohammad R, Taub JW, and Matherly LH (2006) Transcriptional regulation of the human reduced folate carrier in childhood acute lymphoblastic leukemia cells. Clin Cancer Res 12(2):608-616. (Pubitemid 43166156)
96. Liu XY and Matherly LH (2001) Functional interactions between arginine-133 and aspartate-88 in the human reduced folate carrier: evidence for a charge-pair association. Biochem J 358: 511-516. (Pubitemid 32826370)
97. Liu XY, Witt TL, and Matherly LH (2003) Restoration of high-level transport activity by human reduced folate carrier/ThTr1 thiamine transporter chimaeras: role of the transmembrane domain 6/7 linker region in reduced folate carrier function. Biochem J 369:31-37. (Pubitemid 36174122)
98. Louvet C, André T, Gamelin E, Garcia ML, Saavedra A, Lenaers G, de Gramont A, Méry-Mignard D, and Kalla S (2004) A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT11) in previously pretreated metastatic colorectal cancer patients. Bull Cancer 91:279-284.
99. Lu SC (2000) S-Adenosylmethionine. Int J Biochem Cell Biol 32:391-395.
100. Lucock M (2000) Folic acid: nutritional biochemistry, molecular biology, and role in disease processes. Mol Genet Metab 71:121-138.
101. Mahadeo KM, Diop-Bove N, Ramirez SI, Cadilla CL, Rivera E, Martin M, Lerner NB, DiAntonio L, Duva S, Santiago-Borrero PJ, and Goldman ID (2011) Prevalence of a loss-of-function mutation in the proton-coupled folate transporter gene (PCFT-SLC46A1) causing hereditary folate malabsorption in Puerto Rico. J Pediatr 159(4):623-627.
102. Mahadeo K, Diop-Bove N, Shin D, Unal ES, Teo J, Zhao R, Chang MH, Fulterer A, Romero MF, and Goldman ID (2010) Properties of the Arg376 residue of the proton-coupled folate transporter (PCFT-SLC46A1) and a glutamine mutant causing hereditary folate malabsorption. Am J Physiol Cell Physiol 299:C1153-C1161.
103. Mairinger F, Vollbrecht C, Halbwedl I, Hatz M, Stacher E, Gully C, Quehenberger F, Stephan-Falkenau S, Kollmeier J, Roth A, Mairinger T, and Popper H (2013) Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma. J Thorac Oncol 8(5):644-653.
104. Marchant JS, Subramanian VS, Parker I, and Said HM (2002) Intracellular trafficking and membrane targeting mechanisms of the human reduced folate carrier in Mammalian epithelial cells. J Biol Chem 277:33325-33333. (Pubitemid 34984854)
105. Marchi E, Mangone M, Zullo K, and O'Connor OA (2013) Pralatrexate pharmacology and clinical development. Clin Cancer Res 19:6657-6661.
106. Matherly LH, Angeles SM, and McGuire JJ (1993) Determinants of the disparate antitumor activities of (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolate and methotrexate toward human lymphoblastic leukemia cells, characterized by severely impaired antifolate membrane transport. Biochem Pharmacol 46:2185-2195. (Pubitemid 24012310)
107. Matherly LH, Barlowe CK, Phillips VM, and Goldman ID (1987) The effects on 4-amino-antifolates on 5-formyltetrahydrofolate metabolism in L1210 cells. A biochemical basis of the selectivity of leucovorin rescue. J Biol Chem 262:710-717. (Pubitemid 17005241)
108. Matherly LH, Czajkowski CA, and Angeles SM (1991) Identification of a highly glycosylated methotrexate membrane carrier in K562 human erythroleukemia cells up-regulated for tetrahydrofolate cofactor and methotrexate transport. Cancer Res 51:3420-3426.
109. Matherly LH and Gangjee A(2011) Discovery of novel antifolate inhibitors of de novo purine nucleotide biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry, in Targeted Drug Strategies for Cancer and Inflammation (Jackman AL and Leamon CP eds) pp 119-134, Springer Science+Buisness Media, New York.
110. Matherly LH and Goldman DI (2003) Membrane transport of folates. Vitam Horm 66:403-456. (Pubitemid 137640823)
111. Matherly LH and Hou Z (2008) Structure and function of the reduced folate carrier a paradigm of a major facilitator superfamily mammalian nutrient transporter. Vitam Horm 79:145-184.
112. Matherly LH, Hou Z, and Deng Y (2007) Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Rev 26:111-128. (Pubitemid 46452186)
113. Matherly LH and Muench SP (1990) Evidence for a localized conversion of endogenous tetrahydrofolate cofactors to dihydrofolate as an important element in antifolate action in murine leukemia cells. Biochem Pharmacol 39:2005-2014. (Pubitemid 20187339)
114. Matherly LH, Voss MK, Anderson LA, Fry DW, and Goldman ID (1985) Enhanced polyglutamylation of aminopterin relative to methotrexate in the Ehrlich ascites tumor cell in vitro. Cancer Res 45:1073-1078. (Pubitemid 15111262)
115. McGuire JJ, Haile WH, and Yeh CC (2006) 5-amino-4-imidazolecarboxamide riboside potentiates both transport of reduced folates and antifolates by the human reduced folate carrier and their subsequent metabolism. Cancer Res 66:3836-3844.
116. Mendelsohn LG, Worzalla JF, and Walling JM (1999) Preclinical and Clinical Evaluation of the Glycinamide Ribonucleotide Formyltransferase Inhibitors Lometrexol and LY309887, in Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy (Jackman AL, ed, ed) pp 261-280, Humana Press, Inc., Totowa, NJ.
117. Menter A, Thrash B, Cherian C, Matherly LH, Wang L, Gangjee A, Morgan JR, Maeda DY, Schuler AD, and Kahn SJ, et al. (2012) Intestinal transport of aminopterin enantiomers in dogs and humans with psoriasis is stereoselective: evidence for a mechanism involving the proton-coupled folate transporter. J Pharmacol Exp Ther 342:696-708.
118. Meyer E, Kurian MA, Pasha S, Trembath RC, Cole T, and Maher ER (2010) A novel PCFT gene mutation (p.Cys66LeufsX99) causing hereditary folate malabsorption. Mol Genet Metab 99:325-328.
119. Min SH, Oh SY, Karp GI, Poncz M, Zhao R, and Goldman ID (2008) The clinical course and genetic defect in the PCFT gene in a 27-year-old woman with hereditary folate malabsorption. J Pediatr 153:435-437.
120. Mitchell-Ryan S, Wang Y, Raghavan S, Ravindra MP, Hales E, Orr S, Cherian C, Hou Z, Matherly LH, and Gangjee A (2013) Discovery of 5-Substituted Pyrrolo[2,3-d]pyrimidine Antifolates as Dual-Acting Inhibitors of Glycinamide Ribonucleotide Formyltransferase and 5-Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase in De Novo Purine Nucleotide Biosynthesis: Implications of Inhibiting 5-Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase to AMPK Activation and Antitumor Activity. J Med Chem 56:10016-10032.
121. Moccio DM, Sirotnak FM, Samuels LL, Ahmed T, Yagoda A, DeGraw JI, and Piper JR (1984) Similar specificity of membrane transport for folate analogues and their metabolites by murine and human tumor cells: a clinically directed laboratory study. Cancer Res 44:352-357. (Pubitemid 14177762)
122. Monahan BP and Allegra CJ, eds, ed (2011) Antifolates, Lippincott Williams and Wilkins, Philadelphia, PA.
123. Moran RG (1999) Roles of folylpoly-gamma-glutamate synthetase in therapeutics with tetrahydrofolate antimetabolites: an overview. Semin Oncol 26(2, Suppl 6)24-32.
124. Moran RG, Baldwin SW, Taylor EC, and Shih C (1989) The 6S- and 6R-diastereomers of 5, 10-dideaza-5, 6, 7, 8-tetrahydrofolate are equiactive inhibitors of de novo purine synthesis. J Biol Chem 264:21047-21051. (Pubitemid 20017915)
125. Moscow JA, Gong M, He R, Sgagias MK, Dixon KH, Anzick SL, Meltzer PS, and Cowan KH (1995) Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Res 55:3790-3794.
126. Nakai Y, Inoue K, Abe N, Hatakeyama M, Ohta KY, Otagiri M, Hayashi Y, and Yuasa H (2007) Functional characterization of human proton-coupled folate transporter/heme carrier protein 1 heterologously expressed in mammalian cells as a folate transporter. J Pharmacol Exp Ther 322:469-476. (Pubitemid 47105788)
127. Natarajan K, Xie Y, Baer MR, and Ross DD (2012) Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol 83:1084-1103.
128. O'Connor OA, Horwitz S, Hamlin P, Portlock C, Moskowitz CH, Sarasohn D, Neylon E, Mastrella J, Hamelers R, Macgregor-Cortelli B, Patterson M, Seshan VE, Sirotnak F, Fleisher M, Mould DR, Saunders M, and Zelenetz AD (2009) Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 27(26):4357-4364.
129. Pan XQ, Zheng X, Shi G, Wang H, Ratnam M, and Lee RJ (2002) Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood 100:594-602. (Pubitemid 34761124)
130. Payton SG, Haska CL, Flatley RM, Ge Y, and Matherly LH (2007) Effects of 5′ untranslated region diversity on the posttranscriptional regulation of the human reduced folate carrier. Biochim Biophys Acta 1769:131-138. (Pubitemid 46341446)
131. Polgar O, Ierano C, Tamaki A, Stanley B, Ward Y, Xia D, Tarasova N, Robey RW, and Bates SE (2010) Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in transmembrane segment 1 of ABCG2. Biochemistry 49:2235-2245.
132. Prasad PD, Ramamoorthy S, Leibach FH, and Ganapathy V (1995) Molecular cloning of the human placental folate transporter. Biochem Biophys Res Commun 206:681-687.
133. Qiu A, Jansen M, Sakaris A, Min SH, Chattopadhyay S, Tsai E, Sandoval C, Zhao R, Akabas MH, and Goldman ID (2006) Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 127:917-928. (Pubitemid 44792250)
134. Qiu A, Min SH, Jansen M, Malhotra U, Tsai E, Cabelof DC, Matherly LH, Zhao R, Akabas MH, and Goldman ID (2007) Rodent intestinal folate transporters (SLC46A1): secondary structure, functional properties, and response to dietary folate restriction. Am J Physiol Cell Physiol 293:C1669-C1678. (Pubitemid 350085626)
135. Racanelli AC, Rothbart SB, Heyer CL, and Moran RG (2009) Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res 69:5467-5474.
136. Rader JS, Clarke-Pearson D, Moore M, Carson L, Holloway R, Kao MS, Wiznitzer I, and Douglass EC (2003) A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer. Gynecol Oncol 91:318-325. (Pubitemid 37346326)
137. Ray MS, Muggia FM, Leichman CG, Grunberg SM, Nelson RL, Dyke RW, and Moran RG (1993) Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis. J Natl Cancer Inst 85:1154-1159. (Pubitemid 23212282)
138. Reddy JA, Haneline LS, Srour EF, Antony AC, Clapp DW, and Low PS (1999) Expression and functional characterization of the beta-isoform of the folate receptor on CD34(+) cells. Blood 93:3940-3948. (Pubitemid 29249843)
139. Rhee MS, Galivan J, Wright JE, and Rosowsky A (1994) Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells. Mol Pharmacol 45:783-791. (Pubitemid 24139209)
140. Ricart AD, Berlin JD, Papadopoulos KP, Syed S, Drolet DW, Quaratino-Baker C, Horan J, Chick J, Vermeulen W, Tolcher AW, Rowinsky EK, and Rothenberg ML (2008) Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors. Clin Cancer Res 14(23):7947-7955.
141. Roberts JD, Poplin EA, Tombes MB, Kyle B, Spicer DV, Grant S, Synold T, and Moran R (2000) Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation. Cancer Chemother Pharmacol 45:103-110. (Pubitemid 30090240)
142. Roca Lima CS, Orlov SV, Garst J, Manikhas GM, Dowlati A, Quesada JA, Andrews C, Ramirez ML, Choy GS, and Berk G (2006) A phase I study of talotrexin (PT-523) in patients with relapsed or refractory non-small cell lung cancer (NSCLC). J Clin Oncol 24(18S):7142.
143. Rosowsky A, Bader H, Cucchi CA, Moran RG, Kohler W, and Freisheim JH (1988) Methotrexate analogues. 33. N delta-acyl-N alpha-(4-amino-4-deoxypteroyl) -L-ornithine derivatives: synthesis and in vitro antitumor activity. J Med Chem 31:1332-1337.
144. Rosowsky A, Bader H, Wright JE, Keyomarsi K, and Matherly LH (1994) Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 39,5-dichloroaminopterin. J Med Chem 37:2167-2174. (Pubitemid 24228444)
145. Ross JF, Chaudhuri PK, and Ratnam M (1994) Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 73:2432-2443. (Pubitemid 24129130)
146. Rothbart SB, Racanelli AC, and Moran RG (2010) Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas. Cancer Res 70:10299-10309.
147. Rothem L, Stark M, Kaufman Y, Mayo L, and Assaraf YG (2004) Reduced folate carrier gene silencing in multiple antifolate-resistant tumor cell lines is due to a simultaneous loss of function of multiple transcription factors but not promoter methylation. J Biol Chem 279:374-384. (Pubitemid 38044836)
148. Roy K, Tolner B, Chiao JH, and Sirotnak FM (1998) A single amino acid difference within the folate transporter encoded by the murine RFC-1 gene selectively alters its interaction with folate analogues. Implications for intrinsic antifolate resistance and directional orientation of the transporter within the plasma membrane of tumor cells. J Biol Chem 273:2526-2531. (Pubitemid 28133892)
149. Sabharanjak S and Mayor S (2004) Folate receptor endocytosis and trafficking. Adv Drug Deliv Rev 56:1099-1109. (Pubitemid 38496510)
150. Sadlish H, Williams FM, and Flintoff WF (2002) Functional role of arginine 373 in substrate translocation by the reduced folate carrier. J Biol Chem 277:42105-42112. (Pubitemid 35257526)
151. Saier MH, Jr, Beatty JT, Goffeau A, Harley KT, Heijne WH, Huang SC, Jack DL, Jähn PS, Lew K, and Liu J, et al. (1999) The major facilitator superfamily. J Mol Microbiol Biotechnol 1: 257-279. (Pubitemid 129491947)
152. Salazar MD and Ratnam M (2007) The folate receptor: what does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev 26:141-152. (Pubitemid 46452188)
153. Salojin KV, Cabrera RM, Sun W, Chang WC, Lin C, Duncan L, Platt KA, Read R, Vogel P, and Liu Q, et al. (2011) A mouse model of hereditary folate malabsorption: deletion of the PCFT gene leads to systemic folate deficiency. Blood 117:4895-4904.
154. Schmid FA, Sirotnak FM, Otter GM, and DeGraw JI (1985) New folate analogs of the 10-deazaaminopterin series: markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice. Cancer Treat Rep 69:551-553. (Pubitemid 15031407)
155. Schulz J, Keller A, Canfield V, Parker G, and Douglass E (2004) ZD9331 as second- or third-line therapy in patients with advanced colorectal cancer: a phase II multicenter trial. Am J Clin Oncol 27:337-342. (Pubitemid 39045242)
156. Schwartz G, Johnson TR, Goetz A, Burris H, Smetzer L, Lampkin T, Sailstad J, Hohneker JA, Von Hoff DD, and Rowinsky EK (2001) A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies. Clin Cancer Res 7(7):1901-1911. (Pubitemid 32994824)
157. Shane B (1989) Folylpolyglutamate synthesis and role in the regulation of one-carbon metabolism. Vitam Horm 45:263-335.
158. Sharina IG, Zhao R, Wang Y, Babani S, and Goldman ID (2001) Mutational analysis of the functional role of conserved arginine and lysine residues in transmembrane domains of the murine reduced folate carrier. Mol Pharmacol 59:1022-1028. (Pubitemid 32381580)
159. Shayeghi M, Latunde-Dada GO, Oakhill JS, Laftah AH, Takeuchi K, Halliday N, Khan Y, Warley A, McCann FE, and Hider RC, et al. (2005) Identification of an intestinal heme transporter. Cell 122:789-801. (Pubitemid 41242642)
160. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, and Patel VF, et al. (1997) LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57:1116-1123. (Pubitemid 27138611)
161. Shih C and Thornton DE (1999) Preclinical Pharmacology Studies and the Clinical Development of a Novel Multitargeted Antifolate, MTA (LY231514), in Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy (Jackman AL ed) pp 183-201, Humana Press, Inc., Totowa, NJ.
162. Shin DS, Mahadeo K, Min SH, Diop-Bove N, Clayton P, Zhao R, and Goldman ID (2011) Identification of novel mutations in the proton-coupled folate transporter (PCFT-SLC46A1) associated with hereditary folate malabsorption. Mol Genet Metab 103:33-37.
163. Shin DS, Min SH, Russell L, Zhao R, Fiser A, and Goldman ID (2010) Functional roles of aspartate residues of the proton-coupled folate transporter (PCFT-SLC46A1); a D156Y mutation causing hereditary folate malabsorption. Blood 116:5162-5169.
164. Shin DS, Zhao R, Fiser A, and Goldman ID (2013) Role of the fourth transmembrane domain in proton-coupled folate transporter function as assessed by the substituted cysteine accessibility method. Am J Physiol Cell Physiol 304:C1159-C1167.
165. Shin DS, Zhao R, Yap EH, Fiser A, and Goldman ID (2012) A P425R mutation of the proton-coupled folate transporter causing hereditary folate malabsorption produces a highly selective alteration in folate binding. Am J Physiol Cell Physiol 302:C1405-C1412.
166. Sierra EE, Brigle KE, Spinella MJ, and Goldman ID (1997) pH dependence of methotrexate transport by the reduced folate carrier and the folate receptor in L1210 leukemia cells. Further evidence for a third route mediated at low pH. Biochem Pharmacol 53:223-231. (Pubitemid 27013477)
167. Sirotnak FM, Chello PL, Moccio DM, Kisliuk RL, Combepine G, Gaumont Y, and Montgomery JA (1979) Stereospecificity at carbon 6 of fomyltetrahydrofolate as a competitive inhibitor of transport and cytotoxicity of methotrexate in vitro. Biochem Pharmacol 28:2993-2997. (Pubitemid 10236211)
168. Sirotnak FM, DeGraw JI, Colwell WT, and Piper JR (1998) A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice. Cancer Chemother Pharmacol 42:313-318. (Pubitemid 28393849)
169. Sirotnak FM, DeGraw JI, Schmid FA, Goutas LJ, and Moccio DM (1984a) New folate analogs of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models. Cancer Chemother Pharmacol 12:26-30. (Pubitemid 14216734)
170. Sirotnak FM, Moccio DM, and Yang CH (1984b) A novel class of genetic variants of the L1210 cell up-regulated for folate analogue transport inward. Isolation, characterization, and degree of metabolic instability of the system. J Biol Chem 259:13139-13144. (Pubitemid 15223834)
171. Sirotnak FM, Otter GM, and Schmid FA (1993) Markedly improved efficacy of edatrexate compared to methotrexate in a high-dose regimen with leucovorin rescue against metastatic murine solid tumors. Cancer Res 53:587-591. (Pubitemid 23059441)
172. Smith GK, Amyx H, Boytos CM, Duch DS, Ferone R, and Wilson HR (1995) Enhanced antitumor activity for the thymidylate synthase inhibitor 1843U89 through decreased host toxicity with oral folic acid. Cancer Res 55:6117-6125.
173. Smith GK, Bigley JW, Dev IK, Duch DS, Ferone R, and Pendergast W (1999) A Potent, Noncopetitive Thymidylate Synthase Inhibitor-Preclinical and Preliminary Clinical Studies, in Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy (Jackman AL ed) pp 59-100, Humana Press, Inc., Totowa, NJ.
174. Smith D and Gallagher N (2003) A phase II/III study comparing intravenous ZD9331 with gemcitabine in patients with pancreatic cancer. Eur J Cancer 39:1377-1383. (Pubitemid 36773780)
175. Spector R and Lorenzo AV (1975) Folate transport by the choroid plexus in vitro. Science 187: 540-542.
176. Stark M, Gonen N, and Assaraf YG (2009) Functional elements in the minimal promoter of the human proton-coupled folate transporter. Biochem Biophys Res Commun 388:79-85.
177. Steinfeld R, Grapp M, Kraetzner R, Dreha-Kulaczewski S, Helms G, Dechent P, Wevers R, Grosso S, and Gärtner J (2009) Folate receptor alpha defect causes cerebral folate transport deficiency: a treatable neurodegenerative disorder associated with disturbed myelin metabolism. Am J Hum Genet 85:354-363.
178. Stokstad ELR, ed, ed (1990) Historical Perspective on Key Advances in the Biochemistry and Physiology of Folates, Wiley-Liss, New York.
179. Subramanian VS, Chatterjee N, and Said HM (2003) Folate uptake in the human intestine: promoter activity and effect of folate deficiency. J Cell Physiol 196:403-408. (Pubitemid 36775889)
180. Subramanian VS, Marchant JS, and Said HM (2008) Apical membrane targeting and trafficking of the human proton-coupled transporter in polarized epithelia. Am J Physiol Cell Physiol 294: C233-C240.
181. Surmont VF and van Meerbeeck JP (2011) Raltitrexed in mesothelioma. Expert Rev Anticancer Ther 11:1481-1490.
182. Taylor EC, Harrington PJ, Fletcher SR, Beardsley GP, and Moran RG (1985) Synthesis of the antileukemic agents 5,10-dideazaaminopterin and 5,10-dideaza-5,6,7,8-tetrahydroaminopterin. J Med Chem 28:914-921. (Pubitemid 15012500)
183. Taylor EC, Kuhnt D, Shih C, Rinzel SM, Grindey GB, Barredo J, Jannatipour M, and Moran RG (1992) A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem 35:4450-4454.
184. Thompson CA (2009) FDA approves pralatrexate for treatment of rare lymphoma. Am J Health Syst Pharm 66:1890.
185. Tibbetts AS and Appling DR (2010) Compartmentalization of Mammalian folate-mediated onecarbon metabolism. Annu Rev Nutr 30:57-81.
186. Trent DF, Seither RL, and Goldman ID (1991a) Compartmentation of intracellular folates. Failure to interconvert tetrahydrofolate cofactors to dihydrofolate in mitochondria of L1210 leukemia cells treated with trimetrexate. Biochem Pharmacol 42:1015-1019.
187. Trent DF, Seither RL, and Goldman ID (1991b) Rate and extent of interconversion of tetrahydrofolate cofactors to dihydrofolate after cessation of dihydrofolate reductase activity in stationary versus log phase L1210 leukemia cells. J Biol Chem 266:5445-5449. (Pubitemid 21909514)
188. Umapathy NS, Gnana-Prakasam JP, Martin PM, Mysona B, Dun Y, Smith SB, Ganapathy V, and Prasad PD (2007) Cloning and functional characterization of the proton-coupled electrogenic folate transporter and analysis of its expression in retinal cell types. Invest Ophthalmol Vis Sci 48:5299-5305. (Pubitemid 351260944)
189. Unal ES, Zhao R, Chang MH, Fiser A, Romero MF, and Goldman ID (2009a) The functional roles of the His247 and His281 residues in folate and proton translocation mediated by the human proton-coupled folate transporter SLC46A1. J Biol Chem 284:17846-17857.
190. Unal ES, Zhao R, and Goldman ID (2009b) Role of the glutamate 185 residue in proton translocation mediated by the proton-coupled folate transporter SLC46A1. Am J Physiol Cell Physiol 297:C66-C74.
191. Unal ES, Zhao R, Qiu A, and Goldman ID (2008) N-linked glycosylation and its impact on the electrophoretic mobility and function of the human proton-coupled folate transporter (HsPCFT). Biochim Biophys Acta 1778:1407-1414.
192. Visentin M, Unal ES, Zhao R, and Goldman ID (2013) The membrane transport and polyglutamation of pralatrexate: a new-generation dihydrofolate reductase inhibitor. Cancer Chemother Pharmacol 72:597-606.
193. Visentin M, Zhao R, and Goldman ID (2012a) The antifolates. Hematol Oncol Clin North Am 26: 629-648, ix ix.
194. Visentin M, Zhao R, and Goldman ID (2012b) Augmentation of reduced folate carrier-mediated folate/antifolate transport through an antiport mechanism with 5-aminoimidazole-4-carboxamide riboside monophosphate. Mol Pharmacol 82:209-216.
195. Wang L, Cherian C, Desmoulin SK, Polin L, Deng Y, Wu J, Hou Z, White K, Kushner J, and Matherly LH, et al. (2010) Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry. J Med Chem 53:1306-1318.
196. Wang L, Cherian C, Kugel Desmoulin S, Mitchell-Ryan S, Hou Z, Matherly LH, and Gangjee A (2012) Synthesis and biological activity of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl regioisomers as inhibitors of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier. J Med Chem 55:1758-1770.
197. Wang L, Desmoulin SK, Cherian C, Polin L, White K, Kushner J, Fulterer A, Chang MH, Mitchell-Ryan S, and Stout M, et al. (2011) Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits b-glycinamide ribonucleotide formyltransferase. J Med Chem 54:7150-7164.
198. Wang Y, Zhao R, Russell RG, and Goldman ID (2001) Localization of the murine reduced folate carrier as assessed by immunohistochemical analysis. Biochim Biophys Acta 1513:49-54. (Pubitemid 32566374)
199. Webb BA, Chimenti M, Jacobson MP, and Barber DL (2011) Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer 11:671-677.
200. Wessels JA, Huizinga TW, and Guchelaar HJ (2008) Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 47:249-255. (Pubitemid 351267187)
201. Westerhof GR, Schornagel JH, Kathmann I, Jackman AL, Rosowsky A, Forsch RA, Hynes JB, Boyle FT, Peters GJ, and Pinedo HM, et al. (1995) Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity. Mol Pharmacol 48:459-471.
202. Whetstine JR, Flatley RM, and Matherly LH (2002a) The human reduced folate carrier gene is ubiquitously and differentially expressed in normal human tissues: identification of seven noncoding exons and characterization of a novel promoter. Biochem J 367:629-640. (Pubitemid 35305702)
203. Whetstine JR, Gifford AJ, Witt T, Liu XY, Flatley RM, Norris M, Haber M, Taub JW, Ravindranath Y, and Matherly LH (2001) Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G/A variant at position 80 and transport properties of the His (27) and Arg(27) carriers. Clin Cancer Res 7(11):3416-3422. (Pubitemid 33069975)
204. Whetstine JR, Witt TL, and Matherly LH (2002b) The human reduced folate carrier gene is regulated by the AP2 and sp1 transcription factor families and a functional 61-base pair polymorphism. J Biol Chem 277:43873-43880. (Pubitemid 36157810)
205. White JC, Bailey BD, and Goldman ID (1978) Lack of stereospecificity at carbon 6 of methyltetrahydrofolate transport in Ehrlich ascites tumor cells. Carrier-mediated transport of both stereoisomers. J Biol Chem 253:242-245.
206. Williams FM and Flintoff WF (1995) Isolation of a human cDNA that complements a mutant hamster cell defective in methotrexate uptake. J Biol Chem 270:2987-2992.
207. Williams FM, Murray RC, Underhill TM, and Flintoff WF (1994) Isolation of a hamster cDNA clone coding for a function involved in methotrexate uptake. J Biol Chem 269:5810-5816. (Pubitemid 24242956)
208. Wilson KS and Malfair Taylor SC (2009) Raltitrexed: optimism and reality. Expert Opin Drug Metab Toxicol 5:1447-1454.
209. Witt TL, Stapels SE, and Matherly LH (2004) Restoration of transport activity by co-expression of human reduced folate carrier half-molecules in transport-impaired K562 cells: localization of a substrate binding domain to transmembrane domains 7-12. J Biol Chem 279:46755-46763. (Pubitemid 39518324)
210. Wollack JB, Makori B, Ahlawat S, Koneru R, Picinich SC, Smith A, Goldman ID, Qiu A, Cole PD, and Glod J, et al. (2008) Characterization of folate uptake by choroid plexus epithelial cells in a rat primary culture model. J Neurochem 104:1494-1503. (Pubitemid 351316763)
211. Wong SC, Proefke SA, Bhushan A, and Matherly LH (1995) Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport-defective Chinese hamster ovary cells. J Biol Chem 270:17468-17475.
212. Wong SC, Zhang L, Proefke SA, and Matherly LH (1998) Effects of the loss of capacity for N-glycosylation on the transport activity and cellular localization of the human reduced folate carrier. Biochim Biophys Acta 1375:6-12. (Pubitemid 28511388)
213. Wong SC, Zhang L, Witt TL, Proefke SA, Bhushan A, and Matherly LH (1999) Impaired membrane transport in methotrexate-resistant CCRF-CEM cells involves early translation termination and increased turnover of a mutant reduced folate carrier. J Biol Chem 274: 10388-10394.
214. Worm J, Kirkin AF, Dzhandzhugazyan KN, and Guldberg P (2001) Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells. J Biol Chem 276:39990-40000.
215. Wright JE, Vaidya CM, Chen Y, and Rosowsky A (2000) Efficient utilization of the reduced folate carrier in CCRF-CEM human leukemic lymphoblasts by the potent antifolate N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L- ornithine (PT523) and its B-ring analogues. Biochem Pharmacol 60:41-46. (Pubitemid 30243083)
216. Xia W and Low PS (2010) Folate-targeted therapies for cancer. J Med Chem 53:6811-6824.
217. Yang J, Vlashi E, and Low P (2012) Folate-linked drugs for the treatment of cancer and inflammatory diseases. Subcell Biochem 56:163-179.
218. Yun CH, Tse CM, Nath SK, Levine SA, Brant SR, and Donowitz M (1995) Mammalian Na+/H+ exchanger gene family: structure and function studies. Am J Physiol 269:G1-G11.
219. Zhao R, Assaraf YG, and Goldman ID (1998) A mutated murine reduced folate carrier (RFC1) with increased affinity for folic acid, decreased affinity for methotrexate, and an obligatory anion requirement for transport function. J Biol Chem 273:19065-19071. (Pubitemid 28366300)
220. Zhao R, Diop-Bove N, Visentin M, and Goldman ID (2011a) Mechanisms of membrane transport of folates into cells and across epithelia. Annu Rev Nutr 31:177-201.
221. Zhao R, Gao F, Babani S, and Goldman ID (2000) Sensitivity to 5,10-dideazatetrahydrofolate is fully conserved in a murine leukemia cell line highly resistant to methotrexate due to impaired transport mediated by the reduced folate carrier. Clin Cancer Res 6(8):3304-3311. (Pubitemid 30637761)
222. Zhao R, Gao F, and Goldman ID (1999) Discrimination among reduced folates and methotrexate as transport substrates by a phenylalanine substitution for serine within the predicted eighth transmembrane domain of the reduced folate carrier. Biochem Pharmacol 58:1615-1624. (Pubitemid 29467347)
223. Zhao R, Gao F, and Goldman ID (2001a) Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. Biochem Pharmacol 61:857-865. (Pubitemid 32245569)
224. Zhao R, Gao F, and Goldman ID (2002) Reduced folate carrier transports thiamine monophosphate: an alternative route for thiamine delivery into mammalian cells. Am J Physiol Cell Physiol 282:C1512-C1517. (Pubitemid 34663100)
225. Zhao R, Gao F, Hanscom M, and Goldman ID (2004a) A prominent low-pH methotrexate transport activity in human solid tumors: contribution to the preservation of methotrexate pharmacologic activity in HeLa cells lacking the reduced folate carrier. Clin Cancer Res 10(2):718-727. (Pubitemid 38180440)
226. Zhao R, Gao F, Wang Y, Diaz GA, Gelb BD, and Goldman ID (2001b) Impact of the reduced folate carrier on the accumulation of active thiamin metabolites in murine leukemia cells. J Biol Chem 276:1114-1118. (Pubitemid 32096535)
227. Zhao R and Goldman ID (2003) Resistance to antifolates. Oncogene 22:7431-7457. (Pubitemid 37487168)
228. Zhao R and Goldman ID (2007) The molecular identity and characterization of a Proton-coupled Folate Transporter - PCFT; biological ramifications and impact on the activity of pemetrexed. Cancer Metastasis Rev 26:129-139. (Pubitemid 46452187)
229. Zhao R and Goldman ID (2013) Folate and thiamine transporters mediated by facilitative carriers (SLC19A1-3 and SLC46A1) and folate receptors. Mol Aspects Med 34:373-385.
230. Zhao R, Hanscom M, Chattopadhyay S, and Goldman ID (2004b) Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier: association with the presence of a secondary transport pathway. Cancer Res 64:3313-3319. (Pubitemid 38581438)
231. Zhao R, Matherly LH, and Goldman ID (2009a) Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues. Expert Rev Mol Med 11:e4.
232. Zhao R, Min SH, Qiu A, Sakaris A, Goldberg GL, Sandoval C, Malatack JJ, Rosenblatt DS, and Goldman ID (2007) The spectrum of mutations in the PCFT gene, coding for an intestinal folate transporter, that are the basis for hereditary folate malabsorption. Blood 110:1147-1152. (Pubitemid 47281410)
233. Zhao R, Min SH, Wang Y, Campanella E, Low PS, and Goldman ID (2009b) A role for the proton-coupled folate transporter (PCFT-SLC46A1) in folate receptor-mediated endocytosis. J Biol Chem 284:4267-4274.
234. Zhao R, Qiu A, Tsai E, Jansen M, Akabas MH, and Goldman ID (2008) The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier. Mol Pharmacol 74:854-862.
235. Zhao R, Russell RG, Wang Y, Liu L, Gao F, Kneitz B, Edelmann W, and Goldman ID (2001c) Rescue of embryonic lethality in reduced folate carrier-deficient mice by maternal folic acid supplementation reveals early neonatal failure of hematopoietic organs. J Biol Chem 276:10224-10228.
236. Zhao R, Shin DS, Diop-Bove N, Ovits CG, and Goldman ID (2011b) Random mutagenesis of the proton-coupled folate transporter (SLC46A1), clustering of mutations, and the bases for associated losses of function. J Biol Chem 286:24150-24158.
237. Zhao R, Shin DS, Fiser A, and Goldman ID (2012) Identification of a functionally critical GXXG motif and its relationship to the folate binding site of the proton-coupled folate transporter (PCFT-SLC46A1). Am J Physiol Cell Physiol 303:C673-C681.
238. Zhao R, Unal ES, Shin DS, and Goldman ID (2010) Membrane topological analysis of the proton-coupled folate transporter (PCFT-SLC46A1) by the substituted cysteine accessibility method. Biochemistry 49:2925-2931.
239. Zhao R, Visentin M, Suadicani SO, and Goldman ID (2013) Inhibition of the proton-coupled folate transporter (PCFT-SLC46A1) by bicarbonate and other anions. Mol Pharmacol 84:95-103.
240. Zhao R, Wang Y, Gao F, and Goldman ID (2003) Residues 45 and 404 in the murine reduced folate carrier may interact to alter carrier binding and mobility. Biochim Biophys Acta 1613:49-56.